Initial Treatment of COPD with LABA-LAMA Versus LAMA: Real-World Comparative Effectiveness and Safety

Area of Science:

• Pulmonary Medicine
• Pharmacology
• Cardiology

Background:

• Current guidelines recommend long-acting beta2-agonist (LABA) and long-acting muscarinic antagonist (LAMA) combinations (LABA-LAMA) for initial COPD treatment in patients with frequent exacerbations or symptoms.
• Existing evidence primarily derives from studies on patients already receiving treatment, leaving a gap in understanding initial therapy effectiveness for treatment-naïve individuals.
• Real-world data is crucial to validate treatment strategies in newly diagnosed COPD patients.

Purpose of the Study:

• To compare the effectiveness and safety of initiating single-inhaler LABA-LAMA versus LAMA therapy in treatment-naïve COPD patients.
• To assess the incidence of COPD exacerbations and major adverse cardiovascular events (MACE) within one year of treatment initiation.
• To evaluate treatment outcomes based on disease severity (GOLD groups B and E) and lung function (FEV1).

Main Methods:

• A cohort study utilizing the UK's Clinical Practice Research Datalink (2014-2021) identified newly diagnosed COPD patients (≥40 years).
• Compared treatment-naïve initiators of single-inhaler LABA-LAMA (n=16,804) versus LAMA (n=57,295).
• Propensity score weighting was used to adjust for confounding factors and compare outcomes including COPD exacerbation and MACE incidence over one year.

Main Results:

• Overall, LABA-LAMA initiation showed no significant difference in COPD exacerbation risk compared to LAMA (adjusted HR: 1.00).
• LABA-LAMA was associated with reduced exacerbation risk in GOLD group E patients (HR: 0.93) and those with FEV1 < 50% predicted (HR: 0.91).
• LABA-LAMA initiation was linked to a small but significant increase in MACE risk overall (HR: 1.13), though not significant in patients with FEV1 < 50% predicted.

Conclusions:

• Initiating LABA-LAMA therapy may offer benefits in reducing exacerbations for newly diagnosed COPD patients with multiple exacerbations or severe airflow limitation (FEV1 < 50%).
• The observed increase in MACE risk with LABA-LAMA warrants careful consideration, particularly for patients with preserved lung function (FEV1 ≥ 50%).
• A personalized approach to initial COPD pharmacotherapy, considering individual patient characteristics and risks, is supported by these real-world findings.